BR112014000648A2 - classificador para a classificação molecular de mieloma múltiplo - Google Patents

classificador para a classificação molecular de mieloma múltiplo

Info

Publication number
BR112014000648A2
BR112014000648A2 BR112014000648A BR112014000648A BR112014000648A2 BR 112014000648 A2 BR112014000648 A2 BR 112014000648A2 BR 112014000648 A BR112014000648 A BR 112014000648A BR 112014000648 A BR112014000648 A BR 112014000648A BR 112014000648 A2 BR112014000648 A2 BR 112014000648A2
Authority
BR
Brazil
Prior art keywords
multiple myeloma
classifier
diagnosed
molecular classification
prognosis
Prior art date
Application number
BR112014000648A
Other languages
English (en)
Other versions
BR112014000648B1 (pt
Inventor
Sonneveld Pieter
Kuiper Rowan
Original Assignee
Univ Erasmus Med Ct Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus Med Ct Rotterdam filed Critical Univ Erasmus Med Ct Rotterdam
Publication of BR112014000648A2 publication Critical patent/BR112014000648A2/pt
Publication of BR112014000648B1 publication Critical patent/BR112014000648B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "classificador para a classificação molecular de mieloma múltiplo". a presente invenção é no campo de diagnósticos moleculares e refere-se a um método de classificação de amostras obtidas de pacientes diagnosticados com mieloma múltiplo em três aglomerados (clusters) recentemente definidos. a invenção também se refere a um método de determinação do prognóstico de um indivíduo diagnosticado com mieloma múltiplo, bem como um método para a predição da resposta para tratamento de um indivíduo diagnosticado com mieloma múltiplo. mais em particular, a invenção proporciona um método de determinação do resultado da doença ou o prognóstico de um paciente diagnosticado com mieloma múltiplo por meio de classificação do dito paciente em uma categoria de alto risco ou uma categoria de baixo risco, com base em um classificador de gene 92.
BR112014000648A 2011-07-14 2012-07-12 método para determinação do resultado da doença ou o prognóstico de um paciente diagnosticado com mieloma múltiplo por meio de classificação do paciente em uma categoria de alto risco ou baixo risco BR112014000648B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173971A EP2546357A1 (en) 2011-07-14 2011-07-14 A new classifier for the molecular classification of multiple myeloma.
PCT/EP2012/063722 WO2013007795A1 (en) 2011-07-14 2012-07-12 A new classifier for the molecular classification of multiple myeloma

Publications (2)

Publication Number Publication Date
BR112014000648A2 true BR112014000648A2 (pt) 2017-02-14
BR112014000648B1 BR112014000648B1 (pt) 2020-04-07

Family

ID=46506441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000648A BR112014000648B1 (pt) 2011-07-14 2012-07-12 método para determinação do resultado da doença ou o prognóstico de um paciente diagnosticado com mieloma múltiplo por meio de classificação do paciente em uma categoria de alto risco ou baixo risco

Country Status (18)

Country Link
US (3) US9976185B2 (pt)
EP (2) EP2546357A1 (pt)
JP (1) JP6026529B2 (pt)
KR (1) KR101933742B1 (pt)
AU (1) AU2012282437B2 (pt)
BR (1) BR112014000648B1 (pt)
CA (1) CA2841536C (pt)
CL (1) CL2014000103A1 (pt)
DK (1) DK2732048T3 (pt)
EA (1) EA032730B1 (pt)
ES (1) ES2633165T3 (pt)
IL (1) IL230164A (pt)
MX (1) MX346314B (pt)
NZ (1) NZ619896A (pt)
PL (1) PL2732048T3 (pt)
PT (1) PT2732048T (pt)
WO (1) WO2013007795A1 (pt)
ZA (1) ZA201400159B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546357A1 (en) 2011-07-14 2013-01-16 Erasmus University Medical Center Rotterdam A new classifier for the molecular classification of multiple myeloma.
US20190383817A1 (en) * 2016-02-12 2019-12-19 Skylinedx B.V. Predicting response to immunomodulatory drugs (imids) in multiple myeloma patients
WO2018186740A1 (en) 2017-04-04 2018-10-11 Skylinedx B.V Method for identifying gene expression signatures
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
JP2021521857A (ja) * 2018-04-28 2021-08-30 北京▲師▼▲範▼大学 多発性骨髄腫の分子分類およびその適用
CN110218789B (zh) * 2019-04-22 2022-10-04 曾文炳 一种用于预测多发性骨髓瘤患者总体生存率的基因探针组合物及试剂盒
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
CA3159239A1 (en) 2019-11-29 2021-06-03 Pui Leng Loke Novel compounds for treatment of diseases related to dux4 expression
WO2021105474A1 (en) 2019-11-29 2021-06-03 Facio Intellectual Property B.V. New compounds for treatment of diseases related to dux4 expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
CA2466483A1 (en) * 2001-11-07 2003-07-03 John D. Shaughnessy Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US20080187930A1 (en) * 2006-11-07 2008-08-07 Shaughnessy John D Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof
US20080274911A1 (en) * 2006-11-07 2008-11-06 Burington Bart E Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof
EP1964930A1 (en) * 2007-02-28 2008-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Molecular classifier for prognosis in multiple myeloma
WO2010064016A2 (en) * 2008-12-05 2010-06-10 The Institute Of Cancer Research: Royal Cancer Hospital Methods for determining a prognosis in multiple myeloma
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
EP2546357A1 (en) 2011-07-14 2013-01-16 Erasmus University Medical Center Rotterdam A new classifier for the molecular classification of multiple myeloma.

Also Published As

Publication number Publication date
MX346314B (es) 2017-03-15
EP2732048A1 (en) 2014-05-21
PL2732048T3 (pl) 2017-10-31
KR20140044364A (ko) 2014-04-14
IL230164A (en) 2017-12-31
US20180237866A1 (en) 2018-08-23
ZA201400159B (en) 2017-09-27
CA2841536C (en) 2020-09-22
BR112014000648B1 (pt) 2020-04-07
US20140221313A1 (en) 2014-08-07
DK2732048T3 (en) 2017-08-07
US20210010091A1 (en) 2021-01-14
CA2841536A1 (en) 2013-01-17
JP6026529B2 (ja) 2016-11-16
EA201400131A1 (ru) 2014-04-30
US9976185B2 (en) 2018-05-22
JP2014520540A (ja) 2014-08-25
MX2014000440A (es) 2014-07-09
KR101933742B1 (ko) 2018-12-28
ES2633165T3 (es) 2017-09-19
CL2014000103A1 (es) 2014-07-04
EP2732048B1 (en) 2017-05-10
AU2012282437A1 (en) 2014-01-23
AU2012282437B2 (en) 2016-04-21
EP2546357A1 (en) 2013-01-16
NZ619896A (en) 2016-04-29
WO2013007795A1 (en) 2013-01-17
PT2732048T (pt) 2017-07-18
EA032730B1 (ru) 2019-07-31
US10815532B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
BR112014000648A2 (pt) classificador para a classificação molecular de mieloma múltiplo
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
MX2015001068A (es) Analisis, diagnostico y pronostico de autismo y otros trastornos del desarrollo.
Yamada et al. Extracellular vesicles containing microRNA-92a-3p facilitate partial endothelial-mesenchymal transition and angiogenesis in endothelial cells
BR112013010023A2 (pt) algoritimo aperfeiçoado para a detecção de diabetes
Upadhyay et al. 1, 25-Dihydroxyvitamin D3 (1, 25 (OH) 2D3) signaling capacity and the epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC): implications for use of 1, 25 (OH) 2D3 in NSCLC treatment
BR112013027122A2 (pt) método e sistema para analisar características de tecido, e, kit
BRPI0907658A2 (pt) método automatizado e aparelho para determinar uma medição da idade do coração de um indíviduo e meio legível por computador
WO2014008332A3 (en) System and methods for integrated and predictive analysis of molecular, imaging, and clinical data for patient-specific management of diseases
BR112014029988A8 (pt) seleção de simbiotas por triagem de múltiplas associações de hospedeiro-simbionte
BR112014014841A2 (pt) sistema para suporte clínico para o monitoramento de um ou mais pacientes, método para o monitoramento de um ou mais pacientes, um ou mais processadores programados para realizarem o método, e, sistema para a avaliação da estabilidade de uma condição fisiológica de um paciente
Xiong et al. SFTA1P, LINC00968, GATA6‑AS1, TBX5‑AS1, and FEZF1‑AS1 are crucial long non‑coding RNAs associated with the prognosis of lung squamous cell carcinoma
BR112012014060A2 (pt) métodos e reagentes para detecção aprimorada de peptídeos beta-amiloides
Marin et al. Epigenetics modifications and subclinical atherosclerosis in obstructive sleep apnea: the EPIOSA study
Pacheco et al. Development of a validated blood test for nickel sensitization
Leahy et al. Interleukin-15 is associated with disease severity in viral bronchiolitis
NZ628251A (en) Cd8+t-cell subsets as markers for prediction of delayed fracture healing
BR112015027249A2 (pt) método de diagnóstico de câncer
Das et al. DNA methylome-based validation of induced sputum as an effective protocol to study lung immunity: construction of a classifier of pulmonary cell types
Kang et al. The Expression Pattern of Adhesion G Protein-Coupled Receptor F5 Is Related to Cell Adhesion and Metastatic Pathways in Colorectal Cancer—Comprehensive Study Based on In Silico Analysis
Cheng et al. Exploration of effective biomarkers and infiltrating Immune cells in Osteoarthritis based on bioinformatics analysis
Mirra et al. MicroRNA Monitoring in Human Alveolar Macrophages from Patients with Smoking-Related Lung Diseases: A Preliminary Study
Xu et al. Quantifying risk pathway crosstalk mediated by miRNA to screen precision drugs for breast cancer patients
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
Hu-yun et al. Epidemiological analysis of malaria prevalence in Jiangsu Province in 2011

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/07/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.